Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

Autor: Kathleen V. Fitch, Emma M. Kileel, Sara E. Looby, Markella V. Zanni, Laura R. Sanchez, Carl J. Fichtenbaum, Edgar T. Overton, Carlos Malvestutto, Judith A. Aberg, Karin L. Klingman, Beverly Alston-Smith, Judith Lavelle, Anne Rancourt, Sharlaa Badal-Faesen, Sandra Wagner Cardoso, Anchalee Avihingsanon, Sandesh Patil, Craig A. Sponseller, Kathleen Melbourne, Heather J. Ribaudo, Katharine Cooper-Arnold, Patrice Desvigne-Nickens, Udo Hoffmann, Pamela S. Douglas, Steven K. Grinspoon, on behalf of the REPRIEVE Investigators

Publikováno v: HIV Research & Clinical Practice, Vol 21, Iss 1, Pp 11-23 (2020)

Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent cardiovascular disease in people with HIV. REPRIEVE recentl

Externí odkaz: https://doaj.org/article/c1bbcd7120594120b0af18d8c43b3e8f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Autor: Udo Hoffmann, Maria Saumoy, Heather J. Ribaudo, Kiat Ruxrungtham, Triin Umbleja, Pamela S. Douglas, Craig A. Sponseller, Gerald S. Bloomfield, Vicente Estrada, Carl J. Fichtenbaum, Markella V. Zanni, Edgar T. Overton, Judith S. Currier, Kathleen V. Fitch, Judith A. Aberg, Ann Marie Navar, Steven K. Grinspoon, Flavio Bustorff, Anchalee Avihingsanon, Emma M Kileel, Reprieve Investigators, Kathleen Melbourne

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 73, iss 11
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH). Methods Among participants

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523de4e98fcd58bc87a30eaecd701329
https://escholarship.org/uc/item/39g8z3x3

Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Autor: Douglas, Pamela S., Umbleja, Triin, Bloomfield, Gerald S., Fichtenbaum, Carl J., Zanni, Markella V., Overton, Edgar T., Fitch, Kathleen V., Kileel, Emma M., Aberg, Judith A., Currier, Judith, Sponseller, Craig A., Melbourne, Kathleen, Avihingsanon, Anchalee, Bustorff, Flavio, Estrada, Vicente, Ruxrungtham, Kiat, Saumoy, Maria, Navar, Ann Marie, Hoffmann, Udo, Ribaudo, Heather J., Grinspoon, Steven, REPRIEVE investigators

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona

Background: In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH). Methods: Among participan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::28cb169b9473922848684b1c5d85e7aa
http://hdl.handle.net/2445/182347

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.